These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 18502127)

  • 1. 2,5-Diaminopyrimidines and 3,5-disubstituted azapurines as inhibitors of glycogen synthase kinase-3 (GSK-3).
    Lum C; Kahl J; Kessler L; Kucharski J; Lundström J; Miller S; Nakanishi H; Pei Y; Pryor K; Roberts E; Sebo L; Sullivan R; Urban J; Wang Z
    Bioorg Med Chem Lett; 2008 Jun; 18(12):3578-81. PubMed ID: 18502127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of potent and selective thienopyrimidine inhibitors of Aurora kinases.
    McClellan WJ; Dai Y; Abad-Zapatero C; Albert DH; Bouska JJ; Glaser KB; Magoc TJ; Marcotte PA; Osterling DJ; Stewart KD; Davidsen SK; Michaelides MR
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5620-4. PubMed ID: 21778056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification, SAR studies, and X-ray co-crystallographic analysis of a novel furanopyrimidine aurora kinase A inhibitor.
    Coumar MS; Tsai MT; Chu CY; Uang BJ; Lin WH; Chang CY; Chang TY; Leou JS; Teng CH; Wu JS; Fang MY; Chen CH; Hsu JT; Wu SY; Chao YS; Hsieh HP
    ChemMedChem; 2010 Feb; 5(2):255-67. PubMed ID: 20039358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Ustilago maydis Aurora kinase as a novel antifungal target.
    Tückmantel S; Greul JN; Janning P; Brockmeyer A; Grütter C; Simard JR; Gutbrod O; Beck ME; Tietjen K; Rauh D; Schreier PH
    ACS Chem Biol; 2011 Sep; 6(9):926-33. PubMed ID: 21671622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2,4-Diaminopyrimidine MK2 inhibitors. Part II: Structure-based inhibitor optimization.
    Harris CM; Ericsson AM; Argiriadi MA; Barberis C; Borhani DW; Burchat A; Calderwood DJ; Cunha GA; Dixon RW; Frank KE; Johnson EF; Kamens J; Kwak S; Li B; Mullen KD; Perron DC; Wang L; Wishart N; Wu X; Zhang X; Zmetra TR; Talanian RV
    Bioorg Med Chem Lett; 2010 Jan; 20(1):334-7. PubMed ID: 19926477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: protein structure-guided design and SAR.
    Richardson CM; Williamson DS; Parratt MJ; Borgognoni J; Cansfield AD; Dokurno P; Francis GL; Howes R; Moore JD; Murray JB; Robertson A; Surgenor AE; Torrance CJ
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1353-7. PubMed ID: 16325401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I).
    Zhang L; Fan J; Chong JH; Cesena A; Tam BY; Gilson C; Boykin C; Wang D; Aivazian D; Marcotte D; Xiao G; Le Brazidec JY; Piao J; Lundgren K; Hong K; Vu K; Nguyen K; Gan LS; Silvian L; Ling L; Teng M; Reff M; Takeda N; Timple N; Wang Q; Morena R; Khan S; Zhao S; Li T; Lee WC; Taveras AG; Chao J
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5633-7. PubMed ID: 21798738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of the tyrosine kinase EphB4. Part 4: Discovery and optimization of a benzylic alcohol series.
    Barlaam B; Ducray R; Lambert-van der Brempt C; Plé P; Bardelle C; Brooks N; Coleman T; Cross D; Kettle JG; Read J
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2207-11. PubMed ID: 21441027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel 8-arylated purines as inhibitors of glycogen synthase kinase.
    Ibrahim N; Mouawad L; Legraverend M
    Eur J Med Chem; 2010 Aug; 45(8):3389-93. PubMed ID: 20472330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A convenient synthesis and molecular modeling study of novel purine and pyrimidine derivatives as CDK2/cyclin A3 inhibitors.
    Elgazwy AS; Ismail NS; Elzahabi HS
    Bioorg Med Chem; 2010 Nov; 18(21):7639-50. PubMed ID: 20851615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2,4-Diaminopyrimidine MK2 inhibitors. Part I: Observation of an unexpected inhibitor binding mode.
    Argiriadi MA; Ericsson AM; Harris CM; Banach DL; Borhani DW; Calderwood DJ; Demers MD; Dimauro J; Dixon RW; Hardman J; Kwak S; Li B; Mankovich JA; Marcotte D; Mullen KD; Ni B; Pietras M; Sadhukhan R; Sousa S; Tomlinson MJ; Wang L; Xiang T; Talanian RV
    Bioorg Med Chem Lett; 2010 Jan; 20(1):330-3. PubMed ID: 19919896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2.
    Ledeboer MW; Pierce AC; Duffy JP; Gao H; Messersmith D; Salituro FG; Nanthakumar S; Come J; Zuccola HJ; Swenson L; Shlyakter D; Mahajan S; Hoock T; Fan B; Tsai WJ; Kolaczkowski E; Carrier S; Hogan JK; Zessis R; Pazhanisamy S; Bennani YL
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6529-33. PubMed ID: 19857967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 4-Acylamino-6-arylfuro[2,3-d]pyrimidines: potent and selective glycogen synthase kinase-3 inhibitors.
    Maeda Y; Nakano M; Sato H; Miyazaki Y; Schweiker SL; Smith JL; Truesdale AT
    Bioorg Med Chem Lett; 2004 Aug; 14(15):3907-11. PubMed ID: 15225695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and in vitro evaluation of potent kinase inhibitors: Pyrido[1',2':1,5]pyrazolo[3,4-d]pyrimidines.
    Alberti MJ; Auten EP; Lackey KE; McDonald OB; Wood ER; Preugschat F; Cutler GJ; Kane-Carson L; Liu W; Jung DK
    Bioorg Med Chem Lett; 2005 Aug; 15(16):3778-81. PubMed ID: 15993060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-hinge-binding pyrazolo[1,5-a]pyrimidines as potent B-Raf kinase inhibitors.
    Berger DM; Torres N; Dutia M; Powell D; Ciszewski G; Gopalsamy A; Levin JI; Kim KH; Xu W; Wilhelm J; Hu Y; Collins K; Feldberg L; Kim S; Frommer E; Wojciechowicz D; Mallon R
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6519-23. PubMed ID: 19864136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platinum complex as a nanomolar protein kinase inhibitor.
    Williams DS; Carroll PJ; Meggers E
    Inorg Chem; 2007 Apr; 46(8):2944-6. PubMed ID: 17375909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.
    Das J; Moquin RV; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2652-7. PubMed ID: 18359226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
    DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Chai L; Chaffee SC; Deak HL; Epstein LF; Faust T; Gallant P; Gore A; Gu Y; Henkle B; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; Zhao H; Zhu L; Zhu X
    J Med Chem; 2008 Mar; 51(6):1681-94. PubMed ID: 18321037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2.
    Hilton S; Naud S; Caldwell JJ; Boxall K; Burns S; Anderson VE; Antoni L; Allen CE; Pearl LH; Oliver AW; Wynne Aherne G; Garrett MD; Collins I
    Bioorg Med Chem; 2010 Jan; 18(2):707-18. PubMed ID: 20022510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular docking/dynamics studies of Aurora A kinase inhibitors.
    Talele TT; McLaughlin ML
    J Mol Graph Model; 2008 Jun; 26(8):1213-22. PubMed ID: 18096419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.